CORTCorcept Therapeutics Incorporated

HealthcareUSD
$113.90

Price

$113.90+59%1Y
1M+5.6%1Y+59%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average
3/10
Value3
Quality70
Momentum63
Growth34
Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day.

In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR

P/E (TTM)325.4
Market Cap$9.10B
1Y Return+59%
5Y Return+455%

Corcept Therapeutics Incorporated (CORT) reported revenue of $165M in Q1 2026 (quarter ended Mar 31, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 98% and net loss of $32M. For the full year FY2025, revenue was $761M (+13% year on year) and net income $100M.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #106 of 143 by Smart Score

Compare peers
PRAX+0.24%
Praxis Precision Medicines, Inc.
KYMR-0.95%
Kymera Therapeutics, Inc.
HALO-1.7%
Halozyme Therapeutics, Inc.
APGE+0.04%
Apogee Therapeutics, Inc.
TGTX-0.54%
TG Therapeutics, Inc.
IBRX+2.7%
ImmunityBio, Inc.